- The proliferation of clinical data is making it challenging for companies to compete if they lack evidence pertaining to the effects of their products in humans
- Randomised, double-blind, placebo-controlled trials have emerged as the gold standard of clinical evidence for drugs, nutraceuticals and functional foods, with boundaries blurring as these sectors look to meet the needs of the same consumers, but with different purchasing approaches
- Companies struggling to find investment for clinical trials can gain practical insights through case studies with research teams or smaller-scale pilot trials
- CROs and universities are commonly selected as research partners, but there are complex layers that businesses need to consider in their selection process.
Register to access this resource
Registering as a member of Vitafoods Insights will give you free access to premium content including digital magazines, webinars, whitepapers and more.Download